66. IgA nephropathy
199 clinical trials,   214 drugs   (DrugBank: 57 drugs),   32 drug target genes,   128 drug target pathways

Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04573920
(ClinicalTrials.gov)
February 1, 202128/9/2020Atrasentan in Patients With Proteinuric Glomerular DiseasesA Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular DiseasesIgA Nephropathy;Focal Segmental Glomerulosclerosis;Alport Syndrome;Diabetic Kidney Disease;Diabetic Nephropathy Type 2;Immunoglobulin A NephropathyDrug: AtrasentanChinook Therapeutics U.S., Inc.NULLNot yet recruiting18 YearsN/AAll80Phase 2NULL
2NCT04573478
(ClinicalTrials.gov)
December 1, 202012/9/2020Atrasentan in Patients With IgA NephropathyA Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal FunctionIgA Nephropathy;Immunoglobulin A NephropathyDrug: Atrasentan;Drug: PlaceboChinook Therapeutics U.S., Inc.NULLNot yet recruiting18 YearsN/AAll320Phase 3NULL